신장 신경 차단 장치 시장 : 규모, 점유율, 성장률 및 업계 분석, 지역별 동향 및 예측(2026-2034년)

Growth Factors of renal denervation devices Market

The global renal denervation devices market size was valued at USD 228.9 million in 2025. The market is projected to grow from USD 364.2 million in 2026 to USD 2,477.3 million by 2034, exhibiting a CAGR of 27.1% during 2026-2034. North America dominated the global market with a 35.69% share in 2025, supported by FDA-approved systems, improving reimbursement pathways, growing physician familiarity, and increasing adoption across advanced cardiovascular centers.

Renal denervation devices are catheter-based systems used to reduce renal sympathetic nerve activity in patients with uncontrolled or resistant hypertension. Major technologies include radiofrequency and ultrasound-based systems, while chemical or pharmacologic approaches remain at an earlier stage of development.

Renal Denervation Devices Market Trends

A major market trend is the shift from clinical validation toward commercial center activation and procedure expansion. Following regulatory approvals of newer-generation devices, manufacturers are increasingly focusing on physician training, hospital onboarding, patient referral pathways, and real-world evidence generation.

The U.S. approvals of ReCor Medical's Paradise ultrasound system and Medtronic's Symplicity Spyral RF system created an important commercial turning point. CMS coverage under Coverage with Evidence Development is also helping increase hospital and payer confidence.

Market Drivers

The key market driver is the large and growing burden of uncontrolled and resistant hypertension. Patients who fail to achieve adequate blood pressure control despite medication and lifestyle changes require additional treatment options.

Renal denervation is increasingly positioned as an adjunctive procedure rather than a replacement for antihypertensive medication. Improving reimbursement, guideline recognition, and clinical evidence are helping physicians identify more suitable patients and establish structured referral pathways.

Market Restraints and Challenges

Limited reimbursement in some markets, strict patient selection, and cautious physician adoption can restrain growth. Renal denervation is not yet a routine first-line therapy, which limits the immediately addressable population.

Another major challenge is building effective referral networks between primary care, nephrology, cardiology, and interventional specialists. Hospitals also require trained operators, catheterization laboratories, follow-up systems, and sufficient procedure volumes.

Long-term real-world evidence on durability, cost-effectiveness, and outcomes will remain important for broader payer acceptance.

Market Opportunities

The large population of inadequately controlled hypertension patients creates substantial long-term opportunities. Hospitals can establish dedicated hypertension pathways connecting primary care physicians, cardiologists, nephrologists, and interventional teams.

Growth opportunities are particularly attractive in the U.S., Europe, Japan, China, and other markets with established cardiovascular infrastructure. Broader reimbursement and stronger long-term outcome data could eventually expand renal denervation beyond resistant hypertension into wider uncontrolled hypertension populations.

Segmentation Analysis

By product type, radiofrequency-based renal denervation systems dominated the market, supported by physician familiarity with catheter-based ablation and strong commercial availability. Chemical/pharmacologic renal denervation systems are projected to grow at a very high CAGR of 58.3%.

By application, resistant hypertension held the largest share, reflecting initial adoption among difficult-to-control patients. The segment is projected to account for 55.8% of the market in 2026. Uncontrolled hypertension is expected to grow at a 31.1% CAGR.

By end user, hospitals dominated the market due to their catheterization laboratories, imaging infrastructure, and multidisciplinary care capabilities. Hospitals are projected to hold a 79.1% share in 2026, while specialty clinics are expected to grow at a 33.5% CAGR.

Regional Outlook

North America dominated with a market value of USD 81.7 million in 2025. The U.S. market is projected to reach approximately USD 132.6 million in 2026, representing around 36.4% of global revenue.

Europe is expected to reach USD 95.7 million in 2026, supported by established clinical experience and CE-marked systems. Germany is projected at USD 23.6 million, while the U.K. is estimated at USD 15.4 million.

Asia Pacific is projected to reach USD 91.6 million in 2026. China is estimated at USD 31.4 million, Japan at USD 21.0 million, and India at USD 8.7 million.

Latin America is expected to reach approximately USD 22.9 million in 2026, while the GCC market is projected at USD 7.2 million.

Competitive Landscape

The market is highly concentrated, with Medtronic plc and ReCor Medical, Inc. holding leading positions through the Symplicity Spyral and Paradise platforms. Other companies include SyMap Medical, Shanghai Bio-Heart Biological Technology, Shanghai Golden Leaf MedTec, Boston Scientific, Ablative Solutions, Metavention, DeepQure, and Verve Medical.

Competition centers on clinical evidence, regulatory approval, technology platform, physician training, hospital activation, and reimbursement support.

Key Industry Developments

In November 2025, CMS approved the SPYRAL CARE and RADIANCE CED studies. In September 2025, Medtronic received PMDA approval in Japan for Symplicity Spyral. In August 2025, Otsuka Medical Devices received Japanese approval for the Paradise ultrasound system. In May 2025, Boston Scientific completed its acquisition of SoniVie. In February 2025, Shanghai Bio-Heart announced NMPA approval for its Iberis multi-electrode renal artery RF ablation system.

Conclusion

The renal denervation devices market is expected to expand rapidly from USD 228.9 million in 2025 to USD 364.2 million in 2026 and USD 2,477.3 million by 2034, at a CAGR of 27.1% during 2026-2034. Growth will be driven by the rising uncontrolled hypertension burden, improving reimbursement, expanding clinical evidence, physician training, and greater hospital adoption. However, strict patient selection, referral gaps, reimbursement variability, and the need for long-term real-world outcomes may limit faster penetration. North America is expected to retain its leading position, while Europe and Asia Pacific are likely to emerge as major growth markets.

Segmentation By Product Type, Application, End-user, and Region

By Product Type

• Radiofrequency (RF)-based Renal Denervation Systems
• Ultrasound-based Renal Denervation Systems
• Chemical/Pharmacologic Renal Denervation Systems
• Others

By Application

• Resistant Hypertension
• Uncontrolled Hypertension
• Other Cardiovascular & Renal Indications

By End-user

• Hospitals
• Specialty Clinics
• Others

By Geography

• North America (By Product Type, By Application, By End-user, and By Country)
  • U.S. (By Product Type)
  • Canada (By Product Type)
• Europe (By Product Type, By Application, By End-user, and By Country/Sub-region)
  • Germany (By ProductType)
  • U.K. (By Product Type)
  • France (By Product Type)
  • Spain (By Product Type)
  • Italy (By Product Type)
  • Scandinavia (By Product Type)
  • Rest of Europe (By Product Type)
• Asia Pacific (By Product Type, By Application, By End-user, and By Country/Sub-region)
  • China (By Product Type)
  • Japan (By Product Type)
  • India (By Product Type)
  • Australia (By Product Type)
  • Southeast Asia (By Product Type)
  • Rest of Asia Pacific (By Product Type)
• Latin America (By Product Type, By Application, By End-user, and By Country/Sub-region)
  • Brazil (By Product Type)
  • Mexico (By Product Type)
  • Rest of Latin America (By Product Type)
• Middle East & Africa (By Product Type, By Application, By End-user, and By Country/Sub-region)
  • GCC (By Product Type)
  • South Africa (By Product Type)
  • Rest of the Middle East & Africa (By Product Type)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Challenges
• 3.5. Market Trends

4. Key Insights

• 4.1. Advancements in Renal Denervation Devices
• 4.2. New Product Launchers
• 4.3. Key Industry Developments - (Mergers, Acquisitions & Partnerships, etc.)

5. Global Renal Denervation Devices Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product Type
  • 5.1.1. Radiofrequency (RF)-based Renal Denervation Systems
  • 5.1.2. Ultrasound-based Renal Denervation Systems
  • 5.1.3. Chemical/Pharmacologic Renal Denervation Systems
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Resistant Hypertension
  • 5.2.2. Uncontrolled Hypertension
  • 5.2.3. Other Cardiovascular & Renal Indications
• 5.3. Market Analysis, Insights and Forecast - By End-user
  • 5.3.1. Hospitals
  • 5.3.2. Specialty Clinics
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Renal Denervation Devices Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product Type
  • 6.1.1. Radiofrequency (RF)-based Renal Denervation Systems
  • 6.1.2. Ultrasound-based Renal Denervation Systems
  • 6.1.3. Chemical/Pharmacologic Renal Denervation Systems
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Resistant Hypertension
  • 6.2.2. Uncontrolled Hypertension
  • 6.2.3. Other Cardiovascular & Renal Indications
• 6.3. Market Analysis, Insights and Forecast - By End-user
  • 6.3.1. Hospitals
  • 6.3.2. Specialty Clinics
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
    • 6.4.1.1. By Product Type
  • 6.4.2. Canada
    • 6.4.2.1. By Product Type

7. Europe Renal Denervation Devices Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product Type
  • 7.1.1. Radiofrequency (RF)-based Renal Denervation Systems
  • 7.1.2. Ultrasound-based Renal Denervation Systems
  • 7.1.3. Chemical/Pharmacologic Renal Denervation Systems
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Resistant Hypertension
  • 7.2.2. Uncontrolled Hypertension
  • 7.2.3. Other Cardiovascular & Renal Indications
• 7.3. Market Analysis, Insights and Forecast - By End-user
  • 7.3.1. Hospitals
  • 7.3.2. Specialty Clinics
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.4.1. Germany
    • 7.4.1.1. By Product Type
  • 7.4.2. U.K.
    • 7.4.2.1. By Product Type
  • 7.4.3. France
    • 7.4.3.1. By Product Type
  • 7.4.4. Italy
    • 7.4.4.1. By Product Type
  • 7.4.5. Spain
    • 7.4.5.1. By Product Type
  • 7.4.6. Scandinavia
    • 7.4.6.1. By Product Type
  • 7.4.7. Rest of Europe
    • 7.4.7.1. By Product Type

8. Asia Pacific Renal Denervation Devices Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product Type
  • 8.1.1. Radiofrequency (RF)-based Renal Denervation Systems
  • 8.1.2. Ultrasound-based Renal Denervation Systems
  • 8.1.3. Chemical/Pharmacologic Renal Denervation Systems
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Resistant Hypertension
  • 8.2.2. Uncontrolled Hypertension
  • 8.2.3. Other Cardiovascular & Renal Indications
• 8.3. Market Analysis, Insights and Forecast - By End-user
  • 8.3.1. Hospitals
  • 8.3.2. Specialty Clinics
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.4.1. China
    • 8.4.1.1. By Product Type
  • 8.4.2. India
    • 8.4.2.1. By Product Type
  • 8.4.3. Japan
    • 8.4.3.1. By Product Type
  • 8.4.4. Australia
    • 8.4.4.1. By Product Type
  • 8.4.5. Southeast Asia
    • 8.4.5.1. By Product Type
  • 8.4.6. Rest of Asia Pacific
    • 8.4.6.1. By Product Type

9. Latin America Renal Denervation Devices Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product Type
  • 9.1.1. Radiofrequency (RF)-based Renal Denervation Systems
  • 9.1.2. Ultrasound-based Renal Denervation Systems
  • 9.1.3. Chemical/Pharmacologic Renal Denervation Systems
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Resistant Hypertension
  • 9.2.2. Uncontrolled Hypertension
  • 9.2.3. Other Cardiovascular & Renal Indications
• 9.3. Market Analysis, Insights and Forecast - By End-user
  • 9.3.1. Hospitals
  • 9.3.2. Specialty Clinics
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 9.4.1. Brazil
    • 9.4.1.1. By Product Type
  • 9.4.2. Mexico
    • 9.4.2.1. By Product Type
  • 9.4.3. Rest of Latin America
    • 9.4.3.1. By Product Type

10. Middle East & Africa Renal Denervation Devices Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product Type
  • 10.1.1. Radiofrequency (RF)-based Renal Denervation Systems
  • 10.1.2. Ultrasound-based Renal Denervation Systems
  • 10.1.3. Chemical/Pharmacologic Renal Denervation Systems
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Resistant Hypertension
  • 10.2.2. Uncontrolled Hypertension
  • 10.2.3. Other Cardiovascular & Renal Indications
• 10.3. Market Analysis, Insights and Forecast - By End-user
  • 10.3.1. Hospitals
  • 10.3.2. Specialty Clinics
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 10.4.1. South Africa
    • 10.4.1.1. By Product Type
  • 10.4.2. GCC
    • 10.4.2.1. By Product Type
  • 10.4.3. Rest of the Middle East & Africa
    • 10.4.3.1. By Product Type

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Medtronic plc
  • 11.2.2. Recor Medical, Inc.
  • 11.2.3. SyMap Medical Ltd.
  • 11.2.4. Shanghai Bio-Heart Biological Technology Co., Ltd.
  • 11.2.5. Shanghai Golden Leaf MedTec Co., Ltd.
  • 11.2.6. Boston Scientific Corporation
  • 11.2.7. Ablative Solutions, Inc.
  • 11.2.8. Metavention, Inc.
  • 11.2.9. DeepQure Inc.
  • 11.2.10. Verve Medical, Inc.